Clinical Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients Undergoing Mitral Transcatheter Edge‐to‐Edge Repair
- 15 September 2026
- journal article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (6) , 2046-2058
Abstract
Introduction: Adverse cardiovascular outcomes remain common among patients undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER). Despite growing evidence supporting the cardiovascular benefits of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), large‐scale clinical data evaluating their efficacy in this specific population are limited. We aimed to assess cardiovascular outcomes associated with SGLT2i use compared with standard care using a large global research network database. Methods: A retrospective cohort study was conducted using de‐identified patient data from the TriNetX Global Research Network. Adult patients (≥ 18 years) undergoing M‐TEER were included and stratified into SGLT2i and usual care cohorts according to documented SGLT2i exposure before the index M‐TEER procedure. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to evaluate efficacy and safety outcomes at 6 months and 1‐year follow‐up. Results: A total of 6793 patients undergoing M‐TEER were identified, of whom 2192 received SGLT2i therapy. After PSM, 1407 patients remained in each cohort. At 6 months, the primary composite outcome (stroke, all‐cause mortality, and acute heart failure) showed no significant difference between groups (HR 0.90, p = 0.508). However, significant reductions were observed in all‐cause mortality (HR 0.74, p = 0.012) and all‐cause hospitalizations (HR 0.82, p < 0.001). At 1 year, the primary composite outcome remained nonsignificant (HR 0.87, p = 0.244), while reductions in all‐cause mortality (HR 0.76, p = 0.004) and all‐cause hospitalizations (HR 0.83, p < 0.001) persisted. Conclusion: Among patients undergoing M‐TEER, baseline SGLT2i use was associated with lower all‐cause mortality and hospitalization in this observational cohort.Keywords
This publication has 36 references indexed in Scilit:
- Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart FailureJACC: Heart Failure, 2021
- Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysisScientific Reports, 2021
- NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart FailureJACC: Cardiovascular Interventions, 2020
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysisPrimary Care Diabetes, 2018
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- A comparison of 12 algorithms for matching on the propensity scoreStatistics in Medicine, 2013
- Acute and 12-Month Results With Catheter-Based Mitral Valve Leaflet RepairJACC, 2012
- Percutaneous Mitral Repair With the MitraClip SystemJACC, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008